DoW Bone Marrow Failure, Investigator-Initiated Research Award

The Bone Marrow Failure Investigator-Initiated Research Award is offered by the Defense Health Agency through the Congressionally Directed Medical Research Programs under the Bone Marrow Failure Research Program. This program was established to support high-impact biomedical research addressing inherited and acquired bone marrow failure diseases, with a long-term vision of improving patient outcomes and ultimately achieving cures. Since its inception in 2008, the program has funded research with strong scientific merit and translational potential, focusing on conditions such as aplastic anemia, Fanconi anemia, and related syndromes. The funding opportunity is designed to advance mature research ideas and build upon prior discoveries in ways that significantly contribute to understanding disease mechanisms or improving treatment approaches. The primary purpose of this award mechanism is to support investigator-initiated studies that demonstrate strong preliminary data and clear potential for impact. Eligible projects may include translational and clinical research involving preclinical models, human data, or biological specimens, as well as correlative studies tied to ongoing clinical trials. However, the program explicitly excludes clinical trials themselves. The award also supports investigational new drug enabling activities, including compound characterization, pharmacokinetics, toxicology, and related preclinical development work necessary for regulatory submission. Projects must align with at least one of the program’s focus areas, such as identifying effective treatments or improving understanding of disease progression. Funding for this opportunity is limited, with approximately one award expected and a maximum total funding cap of $1.25 million per project over a period of up to three years. The funding covers both direct and indirect costs, subject to institutional negotiated rates. While the program allows collaboration through a partnering principal investigator model, the combined budget for all partners must remain within the overall cap. Allowable costs include research activities, collaboration travel, and dissemination of findings, while clinical trial expenses and excessive travel costs are not permitted. Cost sharing is not required, lowering barriers for eligible applicants. Eligibility for this opportunity is broad and inclusive. Both domestic and international organizations may apply, including academic institutions, nonprofit organizations, for-profit entities, and government-affiliated research organizations. Principal investigators at all career stages are eligible, provided they are affiliated with an eligible organization. The program encourages multidisciplinary collaborations and partnerships across academia, industry, and government entities, particularly those that enhance access to specialized populations or resources relevant to bone marrow failure research. The application process is structured as a two-step submission. Applicants must first submit a pre-application through the electronic biomedical research portal, which includes a concise narrative outlining objectives, background, study design, and anticipated impact. Only those invited following pre-application review may submit a full application. The full application requires detailed documentation including a project narrative, technical and lay abstracts, a statement of work, impact and translation statements, and supporting materials such as biosketches and letters of support. Applications are evaluated through a two-tier review process consisting of peer review for scientific merit and programmatic review for alignment with program priorities. Evaluation criteria emphasize scientific rigor, feasibility, impact, and translational potential. Reviewers assess the strength of preliminary data, appropriateness of study design, and the likelihood that results will advance understanding or treatment of bone marrow failure conditions. Additional considerations include the qualifications of the research team, the quality of collaboration plans, and the feasibility of transitioning findings into clinical or practical applications. Projects that demonstrate strong potential for meaningful clinical impact and alignment with program priorities are most competitive. The timeline for this funding opportunity includes a pre-application deadline in early August 2026, followed by invitations for full applications in mid-September. Full applications are due in early November 2026, with peer review expected in early 2027 and programmatic review shortly thereafter. Awards are anticipated to be made by September 2027. This funding opportunity is part of an annual cycle, and future iterations are expected based on continued congressional appropriations. Applicants are encouraged to begin preparation early due to the complexity of submission requirements and registration prerequisites.

Strong preliminary data and clear translational potential are critical; align closely with BMF focus areas; ensure no clinical trial components are included